
==== Front
Diabetologia
Diabetologia
Diabetologia
0012-186X
1432-0428
Springer Berlin Heidelberg Berlin/Heidelberg

38898303
6201
10.1007/s00125-024-06201-9
Article
eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes
Gao Lei 1
Ramirez Francisco J. 12
Cabrera Jody Tori O. 1
Varghese Mathews V. 3
Watanabe Makiko 3
Tsuji-Hosokawa Atsumi 3
Zheng Qiuyu 14
Yang Mingya 12
Razan Md Rahatullah 1
Kempf Carrie L. 2
Camp Sara M. 2
Wang Jian 5
Garcia Joe G. N. 2
http://orcid.org/0000-0003-1259-8604
Makino Ayako ay.makino@ufl.edu

123
1 grid.266100.3 0000 0001 2107 4242 Department of Medicine, University of California, San Diego, La Jolla, CA USA
2 grid.15276.37 0000 0004 1936 8091 Center for Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, University of Florida, Jupiter, FL USA
3 https://ror.org/03m2x1q45 grid.134563.6 0000 0001 2168 186X Department of Physiology, The University of Arizona, Tucson, AZ USA
4 https://ror.org/00a98yf63 grid.412534.5 Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
5 grid.470124.4 State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
19 6 2024
19 6 2024
2024
67 9 19982011
9 1 2024
25 4 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Aims/hypothesis

Individuals with diabetes are at high risk of cardiovascular complications, which significantly increase morbidity/mortality. Coronary microvascular disease (CMD) is recognised as a critical contributor to the increased cardiac mortality observed in people with diabetes. Therefore, there is an urgent need for treatments that are specific to CMD. eNAMPT (extracellular nicotinamide phosphoribosyltransferase) is a damage-associated molecular pattern and TLR4 ligand, whose plasma levels are elevated in people with diabetes. This study was thus designed to investigate the pathogenic role of intracellular nicotinamide phosphoribosyltransferase (iNAMPT) and eNAMPT in promoting the development of CMD in a preclinical murine model of type 2 diabetes.

Methods

An inducible type 2 diabetic mouse model was generated by a single injection of low-dose streptozocin (75 mg/kg, i.p.) combined with a high-fat diet for 16 weeks. The in vivo effects of i/eNAMPT inhibition on cardiac endothelial cell (CEC) function were evaluated by using Nampt+/− heterozygous mice, chronic administration of eNAMPT-neutralising monoclonal antibody (mAb) or use of an NAMPT enzymatic inhibitor (FK866).

Results

As expected, diabetic wild-type mice exhibited significantly lower coronary flow velocity reserve (CFVR), a determinant of coronary microvascular function, compared with control wild-type mice. eNAMPT plasma levels or expression in CECs were significantly greater in diabetic mice than in control mice. Furthermore, in comparison with diabetic wild-type mice, diabetic Nampt+/− heterozygous mice showed markedly improved CFVR, accompanied by increased left ventricular capillary density and augmented endothelium-dependent relaxation (EDR) in the coronary artery. NAMPT inhibition by FK866 or an eNAMPT-neutralising mAb significantly increased CFVR in diabetic mice. Furthermore, administration of the eNAMPT mAb upregulated expression of angiogenesis- and EDR-related genes in CECs from diabetic mice. Treatment with either eNAMPT or NAD+ significantly decreased CEC migration and reduced EDR in coronary arteries, partly linked to increased production of mitochondrial reactive oxygen species.

Conclusions/interpretation

These data indicate that increased i/eNAMPT expression contributes to the development of diabetic coronary microvascular dysfunction, and provide compelling support for eNAMPT inhibition as a novel and effective therapeutic strategy for CMD in diabetes.

Graphical Abstract

Supplementary Information

The online version of this article (10.1007/s00125-024-06201-9) contains peer-reviewed but unedited supplementary material.

Keywords

Coronary blood flow
Endothelial cell function
Microvascular complications
PBEF
Type 2 diabetes
Visfatin
http://dx.doi.org/10.13039/100000050 National Heart, Lung, and Blood Institute HL126609 HL141387 HL142214 HL146764 http://dx.doi.org/10.13039/100000090 Congressionally Directed Medical Research Programs W81XWH2110472 issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmc

Introduction

Diabetes, the 7th leading cause of death globally due to the comorbid conditions of diabetic cardiomyopathy, obstructive coronary artery disease (CAD), coronary microvascular disease (CMD) or stroke, affects over 37 million people in the USA. CMD is now recognised as a key risk factor for cardiac ischaemia and heart attack [1, 2]. Coronary flow reserve is a well-accepted assessment of coronary microvascular function in patients with CMD [3], and reduced coronary flow velocity reserve (CFVR) is observed in both diabetic patients and preclinical models of diabetes [4–6]. Importantly, diabetic patients with CMD exhibit higher cardiac mortality than non-diabetic patients with CMD or patients with diabetes but without CMD [5]. Current efforts to treat CMD remain reliant on the use of CAD medications, mandating further studies to understand CMD pathogenic mechanisms to develop novel CMD therapeutic approaches in people with diabetes.

The mechanisms responsible for reduced CFVR include microvascular rarefaction, increased vasospasm, attenuated small coronary artery vasodilation and remodelling [2, 7, 8]. Vascular endothelial cells (ECs) play significant roles in revascularisation, regulation of vascular tone and maintenance of anticoagulant level and barrier integrity/function. We and others have shown that capillary density in the heart is decreased in diabetic individuals and animal models of diabetes [6, 9], and that endothelium-dependent relaxation (EDR) in coronary arteries (CAs) is attenuated in animal models of diabetes due to reduced NO bioavailability [10, 11] and impaired endothelium-dependent hyperpolarisation (EDH)-mediated vasodilatation [6]. Therefore, restoring coronary endothelial function in diabetes would improve coronary microvascular function and decrease cardiac mortality in diabetic individuals.

Nicotinamide phosphoribosyltransferase (NAMPT), also known as pre-B cell colony-enhancing factor (PBEF) or visfatin, is encoded by the Nampt gene on human chromosome 7 and mouse chromosome 12, and is expressed in every organ and cell type. Intracellular NAMPT (iNAMPT) and extracellular NAMPT (eNAMPT) are identical proteins named according to their cellular locations. iNAMPT is expressed predominantly in the cytoplasm and nucleus [12], and catalyses the conversion of nicotinamide to nicotinamide mononucleotide, which is a precursor of the cofactor in energy production, NAD+. The concentration of NAD+ is decreased by ageing, due partly to a reduced iNAMPT level, whereas iNAMPT overexpression increases the lifespan of cells [13]. During high demand for NAD+, such as tumorigenesis, NAMPT levels are increased to supply sufficient NAD+ to malignant cells [14, 15]. Therefore, NAMPT is a biomarker for certain types of cancer, and iNAMPT inhibitors have been tested as a cancer therapy in clinical trials [16], albeit without success due to toxicity and limited efficacy. In contrast to iNAMPT, eNAMPT is a damage-associated molecular pattern protein that binds to Toll-like receptor 4 (TLR4) to promote innate immunity inflammatory responses [17]. Sources of eNAMPT include adipose tissue and activated inflammatory cells [14]; however, ECs also produce and release abundant eNAMPT under various stress and injury conditions [18, 19]. Increased eNAMPT levels in the circulation are implicated in the severity of cardiovascular diseases such as cardiac ischaemia [20], acute inflammatory lung injury [21] and pulmonary hypertension [22].

People with diabetes and diabetic animal models exhibit increased plasma or serum eNAMPT concentrations [14, 17, 23, 24], and increased eNAMPT levels are an independent risk factor for type 2 diabetes-induced complications [25, 26]. eNAMPT modulates endothelial function, including regulation of vascular integrity [27], vascular tone [28] and endothelial-to-mesenchymal transition [29]. Excess eNAMPT disrupts endothelial barrier function [27, 30] and attenuates endothelium-dependent vascular relaxation [25, 31]. As information on the role of eNAMPT in regulation of coronary endothelial function in diabetes remains extremely limited, the present study is designed to define the role of i/eNAMPT in coronary microvascular dysfunction in diabetes, and to test whether inhibition of i/eNAMPT exhibits therapeutic efficacy in the mitigation of coronary microvascular disease in diabetic mice.

Methods

Animals

All experimental protocols used in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of California, San Diego (UCSD), the University of Arizona (UA) and the University of Florida (UF), and conformed to the guidance for the care and use of laboratory animals published by the NIH. The universities have been certified by the US Public Health Service, with Animal Welfare Assurance numbers A3033–01 (UCSD), A3248–01 (UA) and A3377-01 (UF), and IACUC protocol numbers S18185 (UCSD), 14–520 (UA) and 24-001-01 (UF). All laboratory personnel were IACUC-certified.

Inducible type 2 diabetes was induced in male C57BL/6 mice (Envigo, USA) at 6 weeks of age by a single injection of low-dose streptozocin (STZ, 75 mg/kg, dissolved in citrate buffer, i.p.) and a high-fat diet (60% energy from fat; Envigo) for 16 weeks from the day of STZ injection [6, 10, 32]. The experiments were performed 16 weeks after diabetic induction. This is a well-established type 2 diabetes mouse model with hyperglycaemia, hyperinsulinaemia, increased body weight, abnormal glucose tolerance, insulin resistance and dyslipidaemia [6, 10, 32, 33]. Mice only fed with a high-fat diet (without STZ injection) develop obesity but rarely develop type 2 diabetes in our laboratory within 16 weeks. Male TALLYHO/Jng (TH) mice were purchased from the Jackson Laboratory (USA) as a polygenic type 2 diabetes model, with male C57BL/6 mice serving as wild-type (Wt) controls according to the Jackson Laboratory guidelines. Wt and TH mice were fed with a standard laboratory diet (13% energy from fat; Lab Diet, USA) and used for experiments at the age of 16–20 weeks. In addition to inducible C57BL/6 diabetic mice and TH mice, a third mouse line was used, consisting of heterozygous Nampt+/− mice on C57BL/6 background as described previously [30]. Homozygous Nampt knockout in mice is embryonically lethal [34]. Wt and Nampt+/− mice were randomly separated into two groups at 6 weeks old and exposed to the method of type 2 diabetes induction described above. The primer sequence information for genotyping is given in electronic supplementary material (ESM) Table 1. Age was matched (age ± 2 weeks) between diabetic and control mice, and transgenic and Wt mice.

Only male mice were used in this study due to differences in the onset of hyperglycaemia and diabetic complications between male and female mice [35, 36]. It has also been reported that the degree of NAMPT deletion in Nampt+/− mice differs between male and female mice [37].

In specific experiments, the NAMPT enzymatic inhibitor FK866 (3 mg/kg) [22, 38] or vehicle (DMSO) was intraperitoneally administered every other day for 4 weeks, starting 12 weeks after diabetes induction. The reported range of effective FK866 doses in mice varies from 0.5 to 100 mg/kg [38, 39], thus the selected dose in this study (3mg/kg) is in the lower range but ultimately proved to be effective in modulating coronary microvascular dysfunction. A humanised eNAMPT-neutralising monoclonal antibody (NAMPT-mAb, ALT-100) [40, 41] was provided by Aqualung Therapeutics (USA). The ALT-100 mAb or human IgG (control) was intraperitoneally administered at 1 mg/kg twice a week for 4 weeks [40].

An oral glucose tolerance test (OGTT) was performed as described previously [6, 10, 32]. After fasting of the mice for 6 h, the glucose levels at baseline were measured (0 min). Mice were then given glucose (2 g/kg body weight) orally, and blood glucose levels were measured at 15, 30 and 60 min after glucose administration. Serum NAMPT concentration was determined using a NAMPT ELISA kit (AdipoGen, USA), and lipid fractions in the plasma were measured using kits from Fujifilm (USA).

Heart dissection was performed under anaesthesia using a mixture of ketamine (100 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.), and all efforts were made to minimise pain during tissue dissection.

Isolation of mouse CECs

Mouse CECs were isolated using a method described previously [42]. Briefly, after flushing blood from the heart, the heart was dissected, minced and incubated with M199 containing 1 mg/ml collagenase II and 0.6 U/ml dispase II for 1 h at 37°C. The digested material was collected and incubated with magnetic beads prepared by incubation of Dynabeads sheep anti-rat IgG with rat anti-mouse CD31 monoclonal antibody (1 μg/ml) at 4°C overnight. The cell suspension was incubated with beads for 1 h at 4°C, and then CECs were captured and isolated using a Dynal magnet (Thermo Fisher Scientific, USA).

Western blot analysis

Protein levels were analysed using SDS–PAGE separation and electrophoretic transfer to nitrocellulose membranes. The primary antibodies used in this study are listed in ESM Table 2.

CFVR measurements

CFVR, rather than coronary flow reserve, was used to assess coronary microvascular function [6] because of the difficulty in precisely measuring coronary arterial diameter in mice [43]. Coronary blood flow velocity (CFV) was measured using a Vevo F2 system (Fujifilm Visual Sonics, Canada). Mice were anaesthetised with isoflurane and kept on a heating pad at 37°C. The resting CFV was obtained at 1% isoflurane. CFVR was defined as the maximal hyperaemic CFV (induced by 2.5% isoflurane) divided by resting CFV (1% isoflurane) (ESM Table 3) [6, 44]. Each experiment was completed within 40 min, and the heart rate was kept above 400 bpm. If the procedure took longer or the heart rate dropped lower than the criteria, the data were eliminated without analysis.

Assessment of capillary density in the heart

The capillary density in the left ventricle was evaluated as described previously [6]. Briefly, the heart was dissected, embedded in OCT compound, frozen in 2-methylbutane precooled with liquid nitrogen, and kept at −80°C until sectioned. Sections (6 µm in thickness) were fixed in 4% formaldehyde for 5 min, blocked with 5% BSA for 30 min, and incubated with Bandeiraea simplicifolia lectin–FITC (BS-l, Sigma Aldrich, USA) for 30 min. BS-l was used to probe the terminal β-galactosyl saccharides associated with ECs on the surface of arterioles, venules and capillaries. The images were captured using a Nikon Eclipse Ti-E microscope (Nikon, Japan) with a 20 × objective lens in a blinded fashion. The capillary count was analysed using ImageJ 1.54 (NIH, USA). The capillary numerical density (number of capillaries per mm2) was calculated for each heart.

Isometric tension measurement in coronary arterial rings

Isometric tension measurement in CAs was performed as described previously [6, 10]. Third-order small CAs were dissected from the hearts and cut into 1 mm segments. The CA rings were mounted on a myograph (DMT, USA) using thin stainless wires (20 μm in diameter), and the resting tension was set at 100 mg. CAs were allowed to equilibrate for 45 min, with washes every 15 min. After equilibration, each CA ring was contracted by treatment with prostaglandin F2α (PGF2α) to generate a similar level of contraction in all groups. EDR was assessed by administration of acetylcholine (ACh), and smooth muscle (SM)-dependent relaxation was assessed by administration of sodium nitroprusside (SNP, an NO donor) in a dose-dependent manner (1 nmol/l to 100 μmol/l). EDH-mediated relaxation was assessed by ACh administration in the presence of 100 µmol/l N-Nitro-L-arginine methylester (l-NAME, an eNOS inhibitor) and 10 μmol/l indomethacin (a cyclooxygenase inhibitor that decreases production of prostaglandin I2 [PGI2]). The degree of relaxation is shown as the percentage of PGF2α-induced contraction.

RNA-seq

mRNA from mouse CECs was isolated using a miRNeasy mini kit (Qiagen, USA), and the RNA samples were sent to the UCSD Institute for Genomic Medicine for bulk RNA-seq. The sequencing libraries were generated using a TruSeq stranded total RNA library preparation kit with rRNA depletion (Illumina, USA). RNA-seq was performed using a NovaSeq 6000 (Illumina), and the data were analysed at the Center for Computational Biology & Bioinformatics at UCSD. We compared the gene expression levels between control mice treated with IgG and diabetic mice treated with IgG, and between diabetic mice treated with IgG and diabetic mice treated with the eNAMPT mAb. Genes with an adjusted p value <0.1 were used to generate a Venn diagram. A heatmap was generated showing the genes significantly altered among the three groups that related to angiogenesis and EDR.

Cell migration assay in human CECs

Human CECs were purchased from commercial suppliers (ESM Table 4) and cultured in EC medium composed of M199 supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 20 μg/ml endothelial cell growth supplement (ECGS), 50 μg/ml d-valine and 16 U/ml heparin. All experiments were performed before passage 10. CECs were plated in a 12-well plate. The next day, the cells were treated with recombinant human wild-type NAMPT (100 ng/ml) or NAD+ (100 nmol/l), and the confluent cells were scratched by a pipette tip in the middle of the well. The plate was placed in an EVOS FL auto imaging system (Thermo Fisher Scientific), maintained at 37°C with 20% O2, and images were taken every 6 h for 24 h. The percentage cell migration was calculated using ImageJ 1.54, and the data were normalised against the occupied area after 24 h incubation for vehicle-treated cells.

Measurement of the concentration of mitochondrial ROS

The concentration of mitochondrial reactive oxygen species (ROS) was measured as described previously [10]. Human CECs were stained for 30 min using 5 μmol/l MitoSOX Red (to measure mitochondrial ROS) and 100 nmol/l MitoTracker Green (to visualise the mitochondrial structure). MitoSOX and MitoTracker Green fluorescence from the cells was imaged using a Nikon Eclipse Ti-E fluorescence microscope with a 60 × objective lens. The structure of the mitochondria was determined by the MitoTracker Green signal, and the fluorescence intensity of the MitoSOX in the mitochondria was measured. The background intensity was subtracted from the cell intensity.

Chemicals

Detailed information on the chemicals used is given in ESM Table 5.

Scientific rigour and statistics

We established proper control experiments for every experimental plan, and performed data analysis in a blinded fashion wherever possible. The numbers of mice and independent experiments are given in the figure legends. Statistical analysis was performed using GraphPad Prism 10. Data are presented as means ± SEM. If the data passed a normality test (Kolmogorov–Smirnov), two-tailed Student’s t test was used to compare two groups, and one-way ANOVA was used for multiple comparisons. If the data did not pass the normality test, a non-parametric test was used (Mann–Whitney for two groups, Kruskal–Wallis for multiple comparisons). Bonferroni’s multiple comparisons test was used as a post hoc test for one-way ANOVA, and Dunn’s test was used as a post hoc test for the Kruskal–Wallis test. A statistical comparison between dose–response curves was performed using two-way ANOVA with a Bonferroni post hoc test. Differences were considered to be statistically significant when the p value was <0.05.

Results

Serum eNAMPT levels and iNAMPT protein expression in CECs are increased in diabetic mice

We have reported that mice in which type 2 diabetes has been induced by low-dose STZ and high-fat diet feeding have CMD, evidenced by reduced CFVR [6, 32]. Using this model, we first tested eNAMPT levels in the serum and iNAMPT levels in CECs. The serum eNAMPT level in diabetic mice was significantly increased in comparison with control mice (Fig. 1a). In addition, iNAMPT protein levels in CEC lysates were significantly higher in diabetic mice compared with CEC lysates from control mice (Fig. 1b); this was also observed in the spontaneous type 2 diabetes TH mice (Fig. 1c).Fig. 1 NAMPT levels in diabetic mice. (a) Serum eNAMPT levels in control mice (Cont, n=5) and inducible type 2 diabetic (T2D) mice (n=4). *p<0.05 vs Cont. (b) iNAMPT protein levels in CECs isolated from control and T2D mice (n=7 per group). *p<0.05 vs Cont. (c) iNAMPT protein levels in CECs isolated from Wt and TH mice (n=10 per group). *p<0.05 vs Wt. Data are means ± SEM; (b, c) relative units vs Cont/Wt

Diabetic Nampt+/− mice exhibit improved coronary endothelial function and restored CFVR

Homozygous Nampt knockout is embryonically lethal; however, heterozygous Nampt knockout (Nampt+/−) mice have exhibited high utility in multiple preclinical studies [22, 30], without visual defects/changes compared with Nampt+/+ (Wt) mice, but with a significant reduction of iNAMPT levels in CECs (Fig. 2a, b). This reduction of iNAMPT did not affect glucose tolerance (Fig. 2c, d), body weight (Fig. 2e) or lipid profiles (Table 1) in Nampt+/− mice with induced diabetes when compared with diabetic Wt mice. Coronary microvascular function determined by CFVR was significantly decreased in diabetic Wt mice compared with control Wt mice, whereas diabetic Nampt+/− mice showed a significant increase in CFVR compared with diabetic Wt mice (Fig. 2f), indicating that iNAMPT reduction improves coronary microvascular function in diabetic mice. Reduced CFVR is primarily caused by decreased capillary density in the left ventricle and attenuated vascular relaxation or enhanced vascular contraction in small CAs. Capillary density was significantly reduced in diabetic Wt mice compared with control Wt and control Nampt+/− mice, whereas diabetic Nampt+/− mice exhibited a significant increase in capillary density (Fig. 2g). We previously reported that EDR is significantly attenuated in inducible diabetic mice compared with the control [6, 10]. Notably, diabetic Nampt+/− mice showed a significant increase in EDR (Fig. 2h) with negligible changes to SM-dependent relaxation (Fig. 2i). These data suggest that increased iNAMPT cellular content in diabetic mice leads to coronary endothelial dysfunction and attenuates coronary microvascular function.Fig. 2 Nampt+/− heterozygous knockout mice exhibit improved coronary microvascular function. (a) Genotype data obtained using tail samples. (b) iNAMPT levels in CECs isolated from Wt and Nampt+/− mice (n=5 per group). *p<0.05 vs Wt; relative units vs Wt. (c) Glucose levels after OGTT and (d) AUC in Cont-Wt (n=8), Cont-NAMPT+/− (n=8), T2D-Wt (n=6) and T2D-NAMPT+/− (n=10). (e) Body weight in Cont-Wt (n=6), Cont-NAMPT+/− (n=5), T2D-Wt (n=5) and T2D-NAMPT+/− (n=9). (f) CFVR in Cont-Wt (n=6), Cont-NAMPT+/− (n=5), T2D-Wt (n=5) and T2D-NAMPT+/− (n=9). (g) Capillary density (NA/mm2; number of capillaries per mm2) in the left ventricle for Cont-Wt (n=8), Cont-NAMPT+/− (n=9), T2D-Wt (n=7) and T2D-NAMPT+/− (n=9). (h) EDR in CAs; n=4 per group. (i) SM-dependent relaxation in CAs; n=4 per group. Data are means ± SEM. (c–i) *p<0.05 vs Cont-Wt; ¶p<0.05 vs Cont-NAMPT+/−; §p<0.05 vs T2D-Wt. Cont-Wt, control Wt mice; Cont-NAMPT+/−, control Nampt+/− mice; T2D-Wt, T2D Wt mice; T2D-NAMPT+/−, T2D Nampt+/− mice

Table 1 Lipid profiles

	TC (mmol/l)	HDL (mmol/l)	TG (mmol/l)	
iNAMPT/eNAMPT inhibition	
 Wt control (n=8)	1.58 ± 0.20	0.65 ± 0.08	0.21 ± 0.03	
 Nampt+/− control (n=9)	1.40 ± 0.16	0.57 ± 0.07	0.18 ± 0.03	
 T2D Wt (n=6)	4.63 ± 0.37*,†	2.34 ± 0.21*,†	0.47 ± 0.07*,†	
 T2D Nampt+/− (n=9)	5.49 ± 0.33*,†	2.62 ± 0.19*,†	0.45 ± 0.05*,†	
iNAMPT inhibition	
 Control + vehicle (n=10)	2.54 ± 0.10	1.51 ± 0.07	0.29 ± 0.08	
 T2D + vehicle (n=10)	5.23 ± 0.12§	2.75 ± 0.07§	0.27 ± 0.08	
 T2D + FK866 (n=10)	4.64 ± 0.37§	2.94 ± 0.47§	0.33 ± 0.08	
eNAMPT inhibition	
 Control + IgG (n=8)	2.09 ± 0.18	1.40 ± 0.08	0.40 ± 0.09	
 T2D + IgG (n=8)	5.88 ± 0.50¶	2.71 ± 0.16¶	0.62 ± 0.07¶	
 T2D + NMAPT mAb (n=8)	6.80 ± 0.40¶	2.99 ± 0.18¶	0.67 ± 0.06¶	
Data are means ± SEM

n indicates the number of mice

*p<0.05 vs Wt control; †p<0.05 vs Nampt+/− control; §p<0.05 vs control + vehicle; ¶p<0.05 vs control + IgG

HDL, plasma HDL; T2D, type 2 diabetes; TC, plasma total cholesterol; TG, plasma triglycerides

i/eNAMPT inhibition improves CMD in diabetic mice

Chronic administration of the cell-permeable and selective NAMPT inhibitor FK866 did not alter the glucose tolerance, body weight or lipid profile in diabetic mice (Fig. 3a–c and Table 1). However, consistent with results in Nampt+/− mice, FK866 administration in diabetic mice significantly improved CFVR (Fig. 3d). Next, we examined the role of eNAMPT in the development of coronary microvascular dysfunction in diabetes. eNAMPT was inhibited by 4 weeks of treatment with eNAMPT-neutralising mAb in diabetic mice. In line with the results from NAMPT inhibition by FK866 and genetic NAMPT reduction in Nampt+/− mice, administration of eNAMPT mAb did not result in alterations to glucose tolerance, body weight or lipid profiles in diabetic mice (Fig. 3e–g and Table 1), but restored coronary microvascular function in diabetes, as evidenced by restoration of the CFVR (Fig. 3h). These data suggest that both iNAMPT and eNAMPT contribute to the development of CMD in diabetes, and that inhibition of either iNAMPT or eNAMPT is sufficient to restore coronary microvascular function in diabetic mice.Fig. 3 NAMPT inhibition restored coronary microvascular function. (a, b) Effect of FK866 on glucose levels after OGTT (a) and AUC (b) in control mice treated with vehicle (Cont + Vehicle; n=10), T2D mice treated with vehicle (T2D + Vehicle; n=9) and T2D mice treated with FK866 (T2D + FK866; n=10). (c) Body weight in Cont + Vehicle mice (n=10), T2D + Vehicle mice (n=9) and T2D + FK866 mice (n=10). (d) CFVR in Cont + Vehicle mice (n=15), T2D + Vehicle mice (n=14) and T2D + FK866 mice (n=15). Data are means ± SEM. *p<0.05 vs Cont + Vehicle; ¶p<0.05 vs T2D + Vehicle. (e, f) Effect of eNAMPT mAb on glucose levels after OGTT (e) and AUC (f) in control mice treated with IgG (Cont + IgG; n=8), T2D mice treated with IgG (T2D + IgG; n=7) and T2D mice treated with eNAMPT mAb (T2D + NAMPT Ab; n=7). (g) Body weight in Cont + IgG mice (n=8), T2D + IgG mice (n=7) and T2D + NAMPT Ab mice (n=7). (h) CFVR in Cont + IgG mice (n=8), T2D + IgG mice (n=6) and T2D + NAMPT Ab mice (n=7). Data are means ± SEM. *p<0.05 vs Cont + IgG; ¶p<0.05 vs T2D + IgG

eNAMPT mAb administration in diabetic mice restores expression levels of mRNAs related to angiogenesis and EDR in CECs

RNA-seq data in isolated CECs revealed 229 significantly differentially expressed genes (DEGs) between control and diabetic mice (diabetic DEGs) and 91 DEGs that were affected by eNAMPT mAb administration in diabetic mice (eNAMPT mAb DEGs), with a total of 15 DEGs being common to both DEG datasets (Fig. 4a). Gene ontology analysis revealed that the diabetic DEGs were related to angiogenesis (Fig. 4b) and Ca2+/K+ handling (Fig. 4c), with expression of these DEGs being rectified in diabetic mice receiving the eNAMPT mAb.Fig. 4 eNAMPT mAb administration in diabetic mice ameliorates mRNA levels for genes related to angiogenesis and EDR. (a) Venn diagram showing the number of significant DEGs in mouse CECs between control mice treated with IgG (Cont + IgG; n=4), T2D mice treated with IgG (T2D + IgG; n=2) and T2D mice treated with eNAMPT mAb (T2D + NAMPT Ab; n=2). (b) Heatmap showing significant DEGs related to angiogenesis. (c) Heatmap showing significant DEGs related to EDR. The Venn diagram and heatmaps were generated using genes with adjusted p values <0.1

NAMPT and NAD+ treatments decrease migration of CECs

Capillary density in tissues is regulated by the balance of EC migration, EC apoptosis and incorporation of endothelial progenitor cells into the injured area. Therefore, the next set of experiments was designed to test the effect of NAMPT and NAD+ on endothelial migration. Figure 5 shows that eNAMPT and NAD+ slightly, but significantly, attenuated endothelial migration, implying that the reduced capillary density seen in diabetes may be due partly to attenuated endothelial migration caused by increased eNAMPT levels.Fig. 5 eNAMPT and NAD+ attenuate endothelial migration. (a) Representative photomicrographs of cell migration in human CECs treated with vehicle, eNAMPT (100 mg/ml) or NAD+ (100 nmol/l). Scale bars, 200 μm. (b) Summarised cell migration data. The data were normalised by the average cell migration percentage in vehicle-treated CECs at 24 h. Data are presented as mean ± SEM for six experiments per group. *p<0.05 vs vehicle

eNAMPT and NAD+ treatments attenuate EDR via increasing mitochondrial ROS formation in CECs

A 1 h treatment with eNAMPT or NAD+ significantly attenuated EDR (Fig. 6a, d) but had minimal effects on either EDH-mediated relaxation (Fig. 6b, e) or SM-dependent relaxation (Fig. 6c, f). To address the hypothesis that NAMPT or NAD+ may alter NO bioavailability in ECs, we measured mitochondrial ROS formation in CECs using mitoSOX. The results showed that eNAMPT or NAD+ treatment significantly increased mitochondrial ROS production in CECs (Fig. 6g–i), suggesting that eNAMPT or NAD+ attenuate EDR due partly to increased ROS generation.Fig. 6 eNAMPT and NAD+ reduce endothelial-dependent relaxation in CAs via increased mitochondrial ROS formation in CECs. (a) EDR in the presence or absence of 100 or 200 ng/ml eNAMPT; nCAs = 6 per group. (b) EDH-mediated relaxation, assessed by ACh administration in the presence of l-NAME (an eNOS inhibitor, 100 µmol/l) and indomethacin (a cyclo-oxygenase inhibitor, 10 µmol/l), with or without NAMPT (100 ng/ml). Vehicle, nCAs = 11; eNAMPT, nCAs = 9. (c) SM-dependent relaxation in the presence or absence of eNAMPT; nCAs = 6 per group. (d) EDR in the presence or absence of NAD+ (100 nmol/l); nCAs = 5 per group. (e) EDH-mediated relaxation in CAs with or without NAD+, assessed by ACh administration in the presence of l-NAME and indomethacin; nCAs = 4 per group. (f) SM-dependent relaxation in the presence or absence of NAD+; nCAs = 7 per group. (g) Photomicrographs of mitochondrial ROS in CECs treated with vehicle, eNAMPT (100 mg/ml) or NAD+ (100 nmol/l). Scale bars, 10 μm. (h) Summarised data showing the average mitochondrial ROS intensity in vehicle- and eNAMPT-treated CECs for six experiments with >110 cells per group. (i) Summarised data showing the average mitochondrial ROS intensity in vehicle- and NAD+-treated CECs for six experiments with >120 cells. Data are means ± SEM; (h, i) relative units vs vehicle. *p<0.05 vs vehicle

Discussion

In addition to CAD, CMD is a significant risk factor for cardiac ischaemia. However, the development of specific CMD treatments lags far behind treatments for CAD due to the lack of informative preclinical CMD models. We show that our diabetic mouse model is an ideal animal model to investigate the mechanisms of CMD induced by diabetes as this mouse model exhibits reduced CFVR without atherosclerotic plaque formation, and displays capillary rarefaction in the left ventricle and attenuated vascular relaxation in small CAs (the leading causes of CMD) [6, 32]. The present study provides compelling support for eNAMPT inhibition as a novel and effective therapeutic strategy for CMD in diabetes.

Diabetic individuals show increased circulating eNAMPT levels [14, 23, 24, 45] as well as increased iNAMPT levels in adipose tissues [46] and mononuclear cells [47]. Goktas et al demonstrated that liver iNAMPT concentrations positively correlate with HOMA-IR values [46]. However, whether i/eNAMPT participates in glucose homeostasis during diabetes remains unclear [45]. We used three methods to alter i/eNAMPT function/availability in diabetic mice, and examined their glucose tolerance, body weight and lipid profiles. Our data show that i/eNAMPT are unlikely to regulate glucose homeostasis and dyslipidaemia in diabetic mice (Figs 2c–e, 3a–c, e–g and Table 1). These data also imply that changes in endothelial function after NAMPT inhibition are not caused by alteration in diabetic status. NAMPT is essential in fundamental physiological functions; however, a pathophysiological increase of NAMPT levels is implicated in the development of many cardiovascular diseases [14, 22, 30]. Diabetic mice show increased eNAMPT levels (Fig. 1a), in agreement with a previous study [17]. As adipose tissue is an important source of eNAMPT [14], the increased body weight in diabetic mice (Fig. 2e) due to fat accumulation may be responsible for increased serum eNAMPT. We also found that iNAMPT levels are increased in CECs from diabetic mice (Fig. 1b, c), which may contribute to the elevated serum eNAMPT levels observed in these mice. Whether the increased eNAMPT levels observed in diabetic humans or preclinical models reflect orchestrated cellular secretion or pyroptotic release via membrane rupture is still unknown.

To our knowledge, we are the first to report that i/eNAMPT inhibition restores coronary microvascular function via improving coronary endothelial function (Fig. 2). Capillary density is regulated by proliferation and migration of mature ECs, endothelial apoptosis, and incorporation of endothelial progenitor cells into the site where ECs are lost or injured. In diabetes, coronary endothelial angiogenesis and migration are attenuated [32] and EC apoptosis in the heart is increased [6, 32]. The reduced NAMPT expression in Nampt+/− mice significantly increased capillary density in diabetic mice (Fig. 2g). eNAMPT mAb administration in diabetic mice also restored mRNA expression levels of genes related to angiogenesis (Fig. 4), and ex vivo data showed that eNAMPT and NAD+ treatment in CECs attenuate EC migration (Fig. 5). These observations suggest that increased serum eNAMPT and eNAMPT/TLR4 signalling attenuate EC migration in the heart, resulting in reduced capillary density in diabetic mice. During tumorigenesis, i/eNAMPT induce cell proliferation and migration [48, 49]. Therefore, it was a total surprise for us to observe that NAMPT attenuates EC migration. Studies have observed the heterogeneity of cells among different tissues [15], while endothelial moiety and function differ significantly among ECs from different organs [50, 51]. Therefore, this unique response of CECs to NAMPT (or the inhibitory effect of NAMPT on CEC migration) requires further investigation to define its mechanisms.

Diabetic Nampt+/− mice showed a significant increase in EDR compared with diabetic Wt mice (Fig. 2h). Furthermore, eNAMPT and NAD+ treatment in CAs significantly attenuated EDR (Fig. 6a, d) without affecting EDH-mediated relaxation (Fig. 6b, e). ACh stimulates the production of NO and prostacyclin and induces membrane hyperpolarisation in ECs. NO, prostacyclin and hyperpolarised potential are then diffused to SM cells and cause vasodilation; this signalling cascade is termed EDR. In the 3rd order of CAs, we observed significant endothelium-derived NO- and EDH-dependent relaxation in control mice, whereas diabetic mice showed attenuated endothelium-derived NO- and EDH-mediated relaxation [6, 10, 11]. As EDH-mediated relaxation was not altered by eNAMPT or NAD+ treatment (Fig. 6b, e), the attenuation of EDR by eNAMPT or NAD+ may be due to reduced endothelium-derived NO-dependent relaxation. NO bioavailability is regulated by NO production and NO degradation. NO production is controlled by eNOS activity, which is Ca2+-dependent [11]. Therefore, the change in expression of genes related to ion channels/pumps by eNAMPT mAb treatment (Fig. 4c) may contribute to restoring endothelium-derived NO-dependent relaxation. We also demonstrate that eNAMPT and NAD+ increase mitochondrial ROS formation, maybe via eNAMPT/TLR4 inflammatory cascade signalling (Fig. 6g, i). Thus, excessive production of mitochondrial ROS elicited by eNAMPT/TLR4 or NAD+ may play a critical role in reducing NO bioavailability and attenuating EDR in CAs in people with diabetes. We previously reported that CECs in diabetic mice produced excess mitochondrial ROS, and that chronic administration of mitoTempol (a mitochondrial ROS scavenger) restored the attenuated EDR in CAs of diabetic mice [10]. In patients with type 2 diabetes, flow-mediated vasodilation (a non-invasive assessment of endothelial function) negatively correlates with plasma eNAMPT concentration [25, 52]. Romacho et al showed that eNAMPT administration attenuates EDR in the mesenteric artery, and that this is restored by treatment with FK866 or TLR4 blocker, implying that increased NAD+ and activation of inflammatory signalling by eNAMPT/TLR4 activation contribute to impairment of EDR by eNAMPT [31]. Vallejo et al also demonstrated that eNAMPT attenuates EDR via overproduction of cytosolic ROS [53]. TLR4 activation has been implicated in attenuated EDR via excess ROS production in ageing mice [54] and spontaneous hypertensive rats [55], or due to reduced eNOS activation in db/db mice [56]. Taken together, these data imply that secretion of eNAMPT, a potent damage-associated molecular pattern and TLR4 ligand, attenuates EDR, which may subsequently lead to the coronary microvascular dysfunction observed in diabetes.

In this study, we used FK866 as an iNAMPT inhibitor, eNAMPT-neutralising mAb as an eNAMPT inhibitor, and Nampt heterozygous knockout mice as an iNAMPT/eNAMPT-inhibited mouse model. FK866 inhibits the enzymatic activity of NAMPT and thus inhibits both iNAMPT and eNAMPT. However, the relevance of the extracellular enzymatic activity of eNAMPT is still uncertain, as decreases in serum nicotinamide mononucleotide (NMN) were never observed after FK866 administration. In addition, there is inconsistent evidence as to whether eNAMPT generates NMN extracellularly and influences cellular function. Whereas the FK866 inhibitor is cell-permeable and effectively inhibits iNAMPT enzymatic activity, the eNAMPT mAb is delivered intraperitoneally and does not access the intracellular compartment to influence intracellular NAD levels.

iNAMPT plays a critical role in maintaining the physiological function of cells by generating NAD+; however, NAD+ application to control ECs or control vessels significantly attenuated endothelial function in our study (Figs 5 and 6), implying that a pathophysiological increase in iNAMPT has a maladaptive effect on endothelial function. Therefore, inhibition of iNAMPT by FK866 showed a beneficial effect on coronary microvascular function in diabetic mice in which iNAMPT is overexpressed above its physiological level.

Our studies using the humanised eNAMPT-neutralising ALT-100 mAb, which is currently in phase 2A clinical trials (ClinicalTrials.gov, NCT05938036), highlight the critical role of circulating eNAMPT as a damage-associated molecular pattern [17]. The ALT-100 mAb has been shown to reduce the severity of diverse preclinical models of non-alcoholic fatty liver disease (NASH)-induced hepatic fibrosis [17], radiation-induced lung fibrosis [57], ischaemia-induced cardiac fibrosis [20] and pulmonary hypertension [22] underscoring the importance of our current findings in diabetic mice with CMD.

In conclusion, we present compelling data indicating that diabetes leads to increased iNAMPT expression in CECs and augmented eNAMPT secretion that subsequently attenuates CEC migration, inhibits EDR in CAs and impairs coronary microvascular function. Our highly translational studies, using global Nampt+/− heterozygous knockout mice, an iNAMPT enzymatic inhibitor and an eNAMPT-neutralising mAb, indicate that NAMPT is a promising therapeutic target for developing novel and unique treatments for CMD in people with diabetes.

Supplementary Information

Below is the link to the electronic supplementary material.ESM 1 (PDF 272 KB)

Abbreviations

ACh Acetylcholine

BS-l Bandeiraea simplicifolia lectin–FITC

CA Coronary artery

CAD Coronary artery disease

CEC Cardiac endothelial cell

CFV Coronary blood flow velocity

CFVR Coronary flow velocity reserve

CMD Coronary microvascular disease

ECs Endothelial cells

EDH Endothelium-dependent hyperpolarisation

EDR Endothelium-dependent relaxation

eNAMPT Extracellular nicotinamide phosphoribosyltransferase

iNAMPT Intracellular nicotinamide phosphoribosyltransferase

Nampt+/− Heterozygous Nampt

ROS Reactive oxygen species

SM Smooth muscle

SNP Sodium nitroprusside

STZ Streptozocin

TH TALLYHO/Jng

TLR4 Toll-like receptor 4

Wt Wild-type

Data availability

All data in the current study are available from the corresponding author upon reasonable request.

Funding

This work was supported by grants from the Department of Defense (W81XWH2110472 to AM) and from the National Heart, Lung and Blood Institute of the NIH (HL146764 to AM, HL142214 to AM, HL141387 to JGNG and HL126609 to JGNG). The RNA-seq performed by the UCSD IGM Genomics Center utilised an Illumina NovaSeq 6000 that was purchased with funding from NIH shared instrument grant (SIG) grant #S10OD026929. The UCSD CCBB is supported by Altman Clinical and Translational Research Institute grant #UL1TR001442. The Visual Sonics Vevo F2 system was purchased with the NIH SIG grant #S10OD032268.

Authors’ relationships and activities

JGNG is the CEO and Founder of Aqualung Therapeutics. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement

LG, FJR and JTOC designed the research studies, conducted the experiments, analysed the data and drafted and reviewed the manuscript. MVV, MW, AT-H, QZ, MY, MRR, CLK and SMC performed the experiments, analysed data and reviewed the manuscript. JW and JGNG contributed to the analysis and interpretation of data and reviewed the manuscript. AM conceived the project, designed the experiments, analysed the data and wrote the manuscript. LG, FJR and JTOC contributed equally to this work. All authors reviewed and approved the version to be published. AM is the guarantor of this work, and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Lei Gao, Francisco J. Ramirez and Jody Tori O. Cabrera contributed equally to this study.
==== Refs
References

1. Bairey Merz CN Pepine CJ Walsh MN Fleg JL Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade Circulation 2017 135 11 1075 1092 10.1161/CIRCULATIONAHA.116.024534 28289007
Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL (2017) Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade. Circulation 135(11):1075–1092. 10.1161/CIRCULATIONAHA.116.02453428289007
2. Sinha A Rahman H Perera D Ischaemia without obstructive coronary artery disease: the pathophysiology of microvascular dysfunction Curr Opin Cardiol 2020 35 6 720 725 10.1097/HCO.0000000000000788 32852345
Sinha A, Rahman H, Perera D (2020) Ischaemia without obstructive coronary artery disease: the pathophysiology of microvascular dysfunction. Curr Opin Cardiol 35(6):720–725. 10.1097/HCO.000000000000078832852345
3. Thakker RA Rodriguez Lozano J Rodriguez Lozano P Coronary microvascular disease Cardiol Ther 2022 11 1 23 31 10.1007/s40119-021-00250-6 34993903
Thakker RA, Rodriguez Lozano J, Rodriguez Lozano P et al (2022) Coronary microvascular disease. Cardiol Ther 11(1):23–31. 10.1007/s40119-021-00250-634993903
4. Nahser PJ Jr Brown RE Oskarsson H Winniford MD Rossen JD Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus Circulation 1995 91 3 635 640 10.1161/01.cir.91.3.635 7828287
Nahser PJ Jr, Brown RE, Oskarsson H, Winniford MD, Rossen JD (1995) Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 91(3):635–640. 10.1161/01.cir.91.3.6357828287
5. Murthy VL Naya M Foster CR Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus Circulation 2012 126 15 1858 1868 10.1161/CIRCULATIONAHA.112.120402 22919001
Murthy VL, Naya M, Foster CR et al (2012) Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 126(15):1858–1868. 10.1161/CIRCULATIONAHA.112.12040222919001
6. Si R Cabrera JTO Tsuji-Hosokawa A HuR/Cx40 downregulation causes coronary microvascular dysfunction in type 2 diabetes JCI Insight 2021 6 21 e147982 10.1172/jci.insight.147982 34747371
Si R, Cabrera JTO, Tsuji-Hosokawa A et al (2021) HuR/Cx40 downregulation causes coronary microvascular dysfunction in type 2 diabetes. JCI Insight 6(21):e147982. 10.1172/jci.insight.14798234747371
7. Camici PG d'Amati G Rimoldi O Coronary microvascular dysfunction: mechanisms and functional assessment Nat Rev Cardiol 2015 12 1 48 62 10.1038/nrcardio.2014.160 25311229
Camici PG, d’Amati G, Rimoldi O (2015) Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol 12(1):48–62. 10.1038/nrcardio.2014.16025311229
8. Kaul S Jayaweera AR Myocardial capillaries and coronary flow reserve J Am Coll Cardiol 2008 52 17 1399 1401 10.1016/j.jacc.2008.07.039 18940530
Kaul S, Jayaweera AR (2008) Myocardial capillaries and coronary flow reserve. J Am Coll Cardiol 52(17):1399–1401. 10.1016/j.jacc.2008.07.03918940530
9. Chung AW Hsiang YN Matzke LA McManus BM van Breemen C Okon EB Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature Circ Res 2006 99 2 140 148 10.1161/01.RES.0000232352.90786.fa 16778129
Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB (2006) Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 99(2):140–148. 10.1161/01.RES.0000232352.90786.fa16778129
10. Cho YE Basu A Dai A Heldak M Makino A Coronary endothelial dysfunction and mitochondrial reactive oxygen species in type 2 diabetic mice Am J Physiol Cell Physiol 2013 305 10 C1033 1040 10.1152/ajpcell.00234.2013 23986204
Cho YE, Basu A, Dai A, Heldak M, Makino A (2013) Coronary endothelial dysfunction and mitochondrial reactive oxygen species in type 2 diabetic mice. Am J Physiol Cell Physiol 305(10):C1033-1040. 10.1152/ajpcell.00234.201323986204
11. Estrada IA Donthamsetty R Debski P STIM1 restores coronary endothelial function in type 1 diabetic mice Circ Res 2012 111 9 1166 1175 10.1161/CIRCRESAHA.112.275743 22896585
Estrada IA, Donthamsetty R, Debski P et al (2012) STIM1 restores coronary endothelial function in type 1 diabetic mice. Circ Res 111(9):1166–1175. 10.1161/CIRCRESAHA.112.27574322896585
12. Audrito V Messana VG Deaglio S NAMPT and NAPRT: Two metabolic enzymes with key roles in inflammation Front Oncol 2020 10 358 10.3389/fonc.2020.00358 32266141
Audrito V, Messana VG, Deaglio S (2020) NAMPT and NAPRT: Two metabolic enzymes with key roles in inflammation. Front Oncol 10:358. 10.3389/fonc.2020.0035832266141
13. Yoshida M Satoh A Lin JB Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice Cell Metab 2019 30 2 329 342 e325 10.1016/j.cmet.2019.05.015 31204283
Yoshida M, Satoh A, Lin JB et al (2019) Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metab 30(2):329-342 e325. 10.1016/j.cmet.2019.05.01531204283
14. Garten A Schuster S Penke M Gorski T de Giorgis T Kiess W Physiological and pathophysiological roles of NAMPT and NAD metabolism Nat Rev Endocrinol 2015 11 9 535 546 10.1038/nrendo.2015.117 26215259
Garten A, Schuster S, Penke M, Gorski T, de Giorgis T, Kiess W (2015) Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev Endocrinol 11(9):535–546. 10.1038/nrendo.2015.11726215259
15. Lin TC The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis Cancer Manag Res 2019 11 3481 3491 10.2147/CMAR.S199597 31114381
Lin TC (2019) The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis. Cancer Manag Res 11:3481–3491. 10.2147/CMAR.S19959731114381
16. Heske CM Beyond energy metabolism: exploiting the additional roles of NAMPT for cancer therapy Front Oncol 2019 9 1514 10.3389/fonc.2019.01514 32010616
Heske CM (2019) Beyond energy metabolism: exploiting the additional roles of NAMPT for cancer therapy. Front Oncol 9:1514. 10.3389/fonc.2019.0151432010616
17. Sun BL Sun X Kempf CL Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis FASEB J 2023 37 3 e22825 10.1096/fj.202201972RR 36809677
Sun BL, Sun X, Kempf CL et al (2023) Involvement of eNAMPT/TLR4 inflammatory signaling in progression of non-alcoholic fatty liver disease, steatohepatitis, and fibrosis. FASEB J 37(3):e22825. 10.1096/fj.202201972RR36809677
18. Romacho T Villalobos LA Cercas E Carraro R Sanchez-Ferrer CF Peiro C Visfatin as a novel mediator released by inflamed human endothelial cells PLoS One 2013 8 10 e78283 10.1371/journal.pone.0078283 24130902
Romacho T, Villalobos LA, Cercas E, Carraro R, Sanchez-Ferrer CF, Peiro C (2013) Visfatin as a novel mediator released by inflamed human endothelial cells. PLoS One 8(10):e78283. 10.1371/journal.pone.007828324130902
19. Oita RC Camp SM Ma W Novel mechanism for nicotinamide phosphoribosyltransferase inhibition of TNF-α-mediated apoptosis in human lung endothelial cells Am J Respir Cell Mol Biol 2018 59 1 36 44 10.1165/rcmb.2017-0155OC 29337590
Oita RC, Camp SM, Ma W et al (2018) Novel mechanism for nicotinamide phosphoribosyltransferase inhibition of TNF-α-mediated apoptosis in human lung endothelial cells. Am J Respir Cell Mol Biol 59(1):36–44. 10.1165/rcmb.2017-0155OC29337590
20. Liu Z Sammani S Barber CJ An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunction Biomed Pharmacother 2023 170 116103 10.1016/j.biopha.2023.116103 38160623
Liu Z, Sammani S, Barber CJ et al (2023) An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunction. Biomed Pharmacother 170:116103. 10.1016/j.biopha.2023.11610338160623
21. Bime C Casanova NG Camp SM Circulating eNAMPT as a biomarker in the critically ill: acute pancreatitis, sepsis, trauma, and acute respiratory distress syndrome BMC Anesthesiol 2022 22 1 182 10.1186/s12871-022-01718-1 35705899
Bime C, Casanova NG, Camp SM et al (2022) Circulating eNAMPT as a biomarker in the critically ill: acute pancreatitis, sepsis, trauma, and acute respiratory distress syndrome. BMC Anesthesiol 22(1):182. 10.1186/s12871-022-01718-135705899
22. Chen J Sysol JR Singla S Nicotinamide phosphoribosyltransferase promotes pulmonary vascular remodeling and is a therapeutic target in pulmonary arterial hypertension Circulation 2017 135 16 1532 1546 10.1161/CIRCULATIONAHA.116.024557 28202489
Chen J, Sysol JR, Singla S et al (2017) Nicotinamide phosphoribosyltransferase promotes pulmonary vascular remodeling and is a therapeutic target in pulmonary arterial hypertension. Circulation 135(16):1532–1546. 10.1161/CIRCULATIONAHA.116.02455728202489
23. Chang YH Chang DM Lin KC Shin SJ Lee YJ Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review Diabetes Metab Res Rev 2011 27 6 515 527 10.1002/dmrr.1201 21484978
Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ (2011) Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 27(6):515–527. 10.1002/dmrr.120121484978
24. Sayers SR Beavil RL Fine NHF Structure-functional changes in eNAMPT at high concentrations mediate mouse and human β cell dysfunction in type 2 diabetes Diabetologia 2020 63 2 313 323 10.1007/s00125-019-05029-y 31732790
Sayers SR, Beavil RL, Fine NHF et al (2020) Structure-functional changes in eNAMPT at high concentrations mediate mouse and human β cell dysfunction in type 2 diabetes. Diabetologia 63(2):313–323. 10.1007/s00125-019-05029-y31732790
25. Yilmaz MI Saglam M Qureshi AR Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin Nephrol Dial Transplant 2008 23 5 1621 1627 10.1093/ndt/gfm828 18175782
Yilmaz MI, Saglam M, Qureshi AR et al (2008) Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 23(5):1621–1627. 10.1093/ndt/gfm82818175782
26. Kadoglou NP Sailer N Moumtzouoglou A Visfatin (NAMPT) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes Exp Clin Endocrinol Diabetes 2010 118 2 75 80 10.1055/s-0029-1237360 19834878
Kadoglou NP, Sailer N, Moumtzouoglou A et al (2010) Visfatin (NAMPT) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 118(2):75–80. 10.1055/s-0029-123736019834878
27. Ye SQ Zhang LQ Adyshev D Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation Microvasc Res 2005 70 3 142 151 10.1016/j.mvr.2005.08.003 16188281
Ye SQ, Zhang LQ, Adyshev D et al (2005) Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res 70(3):142–151. 10.1016/j.mvr.2005.08.00316188281
28. Romacho T Sanchez-Ferrer CF Peiro C Visfatin/Nampt: an adipokine with cardiovascular impact Mediators Inflamm 2013 2013 946427 10.1155/2013/946427 23843684
Romacho T, Sanchez-Ferrer CF, Peiro C (2013) Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013:946427. 10.1155/2013/94642723843684
29. Ahmed M Zaghloul N Zimmerman P Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb Pulm Circ 2021 11 4 20458940211059712 10.1177/20458940211059712 34790349
Ahmed M, Zaghloul N, Zimmerman P et al (2021) Endothelial eNAMPT drives EndMT and preclinical PH: rescue by an eNAMPT-neutralizing mAb. Pulm Circ 11(4):20458940211059710. 10.1177/2045894021105971234790349
30. Hong SB Huang Y Moreno-Vinasco L Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury Am J Respir Crit Care Med 2008 178 6 605 617 10.1164/rccm.200712-1822OC 18658108
Hong SB, Huang Y, Moreno-Vinasco L et al (2008) Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury. Am J Respir Crit Care Med 178(6):605–617. 10.1164/rccm.200712-1822OC18658108
31. Romacho T Valencia I Ramos-Gonzalez M Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome Sci Rep 2020 10 1 5386 10.1038/s41598-020-62190-w 32214150
Romacho T, Valencia I, Ramos-Gonzalez M et al (2020) Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome. Sci Rep 10(1):5386. 10.1038/s41598-020-62190-w32214150
32. Cabrera JT Si R Tsuji-Hosokawa A Restoration of coronary microvascular function by OGA overexpression in a high-fat diet with low-dose streptozotocin-induced type 2 diabetic mice Diab Vasc Dis Res 2023 20 3 14791641231173630 10.1177/14791641231173630 37186669
Cabrera JT, Si R, Tsuji-Hosokawa A et al (2023) Restoration of coronary microvascular function by OGA overexpression in a high-fat diet with low-dose streptozotocin-induced type 2 diabetic mice. Diab Vasc Dis Res 20(3):14791641231173630. 10.1177/1479164123117363037186669
33. Furman BL Streptozotocin-Induced diabetic models in mice and rats Curr Protoc 2021 1 4 e78 10.1002/cpz1.78 33905609
Furman BL (2021) Streptozotocin-Induced diabetic models in mice and rats. Curr Protoc 1(4):e78. 10.1002/cpz1.7833905609
34. Zhang LQ Van Haandel L Xiong M Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase Cell Death Dis 2017 8 3 e2705 10.1038/cddis.2017.132 28333140
Zhang LQ, Van Haandel L, Xiong M et al (2017) Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase. Cell Death Dis 8(3):e2705. 10.1038/cddis.2017.13228333140
35. Kim JH Stewart TP Soltani-Bejnood M Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice J Endocrinol 2006 191 2 437 446 10.1677/joe.1.06647 17088413
Kim JH, Stewart TP, Soltani-Bejnood M et al (2006) Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J Endocrinol 191(2):437–446. 10.1677/joe.1.0664717088413
36. Han X Shaligram S Zhang R Anderson L Rahimian R Sex-specific vascular responses of the rat aorta: effects of moderate term (intermediate stage) streptozotocin-induced diabetes Can J Physiol Pharmacol 2016 94 4 408 415 10.1139/cjpp-2015-0272 26845285
Han X, Shaligram S, Zhang R, Anderson L, Rahimian R (2016) Sex-specific vascular responses of the rat aorta: effects of moderate term (intermediate stage) streptozotocin-induced diabetes. Can J Physiol Pharmacol 94(4):408–415. 10.1139/cjpp-2015-027226845285
37. Revollo JR Korner A Mills KF Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme Cell Metab 2007 6 5 363 375 10.1016/j.cmet.2007.09.003 17983582
Revollo JR, Korner A, Mills KF et al (2007) Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab 6(5):363–375. 10.1016/j.cmet.2007.09.00317983582
38. Moreno-Vinasco L Quijada H Sammani S Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury Am J Respir Cell Mol Biol 2014 51 2 223 228 10.1165/rcmb.2012-0519OC 24588101
Moreno-Vinasco L, Quijada H, Sammani S et al (2014) Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury. Am J Respir Cell Mol Biol 51(2):223–228. 10.1165/rcmb.2012-0519OC24588101
39. Zeng M Wei TF Chen C Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment J Cereb Blood Flow Metab 2021 41 10 2510 2523 10.1177/0271678X211006291 33818184
Zeng M, Wei TF, Chen C et al (2021) Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment. J Cereb Blood Flow Metab 41(10):2510–2523. 10.1177/0271678X21100629133818184
40. Quijada H Bermudez T Kempf CL Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody Eur Respir J 2021 57 5 2002536 10.1183/13993003.02536-2020 33243842
Quijada H, Bermudez T, Kempf CL et al (2021) Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody. Eur Respir J 57(5):2002536. 10.1183/13993003.02536-202033243842
41. Sun BL Sun X Casanova N Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: novel biomarker and therapeutic target EBioMedicine 2020 61 103059 10.1016/j.ebiom.2020.103059 33045468
Sun BL, Sun X, Casanova N et al (2020) Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: novel biomarker and therapeutic target. EBioMedicine 61:103059. 10.1016/j.ebiom.2020.10305933045468
42. Luo S Truong AH Makino A Isolation of mouse coronary endothelial cells J Vis Exp 2016 113 e53985 10.3791/5398510.3791/53985
Luo S, Truong AH, Makino A (2016) Isolation of mouse coronary endothelial cells. J Vis Exp 113:e53985. 10.3791/5398510.3791/53985
43. Wikstrom J Gronros J Gan LM Adenosine induces dilation of epicardial coronary arteries in mice: relationship between coronary flow velocity reserve and coronary flow reserve in vivo using transthoracic echocardiography Ultrasound Med Biol 2008 34 7 1053 1062 10.1016/j.ultrasmedbio.2007.12.004 18313201
Wikstrom J, Gronros J, Gan LM (2008) Adenosine induces dilation of epicardial coronary arteries in mice: relationship between coronary flow velocity reserve and coronary flow reserve in vivo using transthoracic echocardiography. Ultrasound Med Biol 34(7):1053–1062. 10.1016/j.ultrasmedbio.2007.12.00418313201
44. You J Wu J Ge J Zou Y Comparison between adenosine and isoflurane for assessing the coronary flow reserve in mouse models of left ventricular pressure and volume overload Am J Physiol Heart Circ Physiol 2012 303 10 H1199 1207 10.1152/ajpheart.00612.2012 23001834
You J, Wu J, Ge J, Zou Y (2012) Comparison between adenosine and isoflurane for assessing the coronary flow reserve in mouse models of left ventricular pressure and volume overload. Am J Physiol Heart Circ Physiol 303(10):H1199-1207. 10.1152/ajpheart.00612.201223001834
45. Dakroub A Nasser SA Younis N Visfatin: a possible role in cardiovasculo-metabolic disorders Cells 2020 9 11 2444 10.3390/cells9112444 33182523
Dakroub A, Nasser SA, Younis N et al (2020) Visfatin: a possible role in cardiovasculo-metabolic disorders. Cells 9(11):2444. 10.3390/cells911244433182523
46. Goktas Z Owens S Boylan M Associations between tissue visfatin/nicotinamide, phosphoribosyltransferase (Nampt), retinol binding protein-4, and vaspin concentrations and insulin resistance in morbidly obese subjects Mediators Inflamm 2013 2013 861496 10.1155/2013/861496 24367155
Goktas Z, Owens S, Boylan M et al (2013) Associations between tissue visfatin/nicotinamide, phosphoribosyltransferase (Nampt), retinol binding protein-4, and vaspin concentrations and insulin resistance in morbidly obese subjects. Mediators Inflamm 2013:861496. 10.1155/2013/86149624367155
47. Tsiotra PC Tsigos C Yfanti E Visfatin, TNF-α and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women Horm Metab Res 2007 39 10 758 763 10.1055/s-2007-990288 17952840
Tsiotra PC, Tsigos C, Yfanti E et al (2007) Visfatin, TNF-α and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 39(10):758–763. 10.1055/s-2007-99028817952840
48. Song Y Yang L Xu M Boosted photocatalytic activity induced NAMPT-Regulating therapy based on elemental bismuth-humic acids heterojunction for inhibiting tumor proliferation/migration/inflammation Biomaterials 2020 254 120140 10.1016/j.biomaterials.2020.120140 32473481
Song Y, Yang L, Xu M et al (2020) Boosted photocatalytic activity induced NAMPT-Regulating therapy based on elemental bismuth-humic acids heterojunction for inhibiting tumor proliferation/migration/inflammation. Biomaterials 254:120140. 10.1016/j.biomaterials.2020.12014032473481
49. Zhao H Tang W Chen X The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells Biochem Biophys Res Commun 2017 493 1 77 84 10.1016/j.bbrc.2017.09.071 28919418
Zhao H, Tang W, Chen X et al (2017) The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells. Biochem Biophys Res Commun 493(1):77–84. 10.1016/j.bbrc.2017.09.07128919418
50. Huang X Jia L Qian Z Diversity in human placental microvascular endothelial cells and macrovascular endothelial cells Cytokine 2018 111 287 294 10.1016/j.cyto.2018.09.009 30269024
Huang X, Jia L, Qian Z et al (2018) Diversity in human placental microvascular endothelial cells and macrovascular endothelial cells. Cytokine 111:287–294. 10.1016/j.cyto.2018.09.00930269024
51. Mathur T Tronolone JJ Jain A Comparative analysis of blood-derived endothelial cells for designing next-generation personalized organ-on-chips J Am Heart Assoc 2021 10 22 e022795 10.1161/JAHA.121.022795 34743553
Mathur T, Tronolone JJ, Jain A (2021) Comparative analysis of blood-derived endothelial cells for designing next-generation personalized organ-on-chips. J Am Heart Assoc 10(22):e022795. 10.1161/JAHA.121.02279534743553
52. Takebayashi K Suetsugu M Wakabayashi S Aso Y Inukai T Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus Metabolism 2007 56 4 451 458 10.1016/j.metabol.2006.12.001 17378999
Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56(4):451–458. 10.1016/j.metabol.2006.12.00117378999
53. Vallejo S Romacho T Angulo J Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity PLoS One 2011 6 11 e27299 10.1371/journal.pone.0027299 22073309
Vallejo S, Romacho T, Angulo J et al (2011) Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One 6(11):e27299. 10.1371/journal.pone.002729922073309
54. Liu H Chu S Wu Z Loss of toll-like receptor 4 ameliorates cardiovascular dysfunction in aged mice Immun Ageing 2021 18 1 42 10.1186/s12979-021-00251-y 34740366
Liu H, Chu S, Wu Z (2021) Loss of toll-like receptor 4 ameliorates cardiovascular dysfunction in aged mice. Immun Ageing 18(1):42. 10.1186/s12979-021-00251-y34740366
55. De Batista PR Palacios R Martin A Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production PLoS One 2014 9 8 e104020 10.1371/journal.pone.0104020 25093580
De Batista PR, Palacios R, Martin A et al (2014) Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PLoS One 9(8):e104020. 10.1371/journal.pone.010402025093580
56. Zhu Z Peng X Li X HMGB1 impairs endothelium-dependent relaxation in diabetes through TLR4/eNOS pathway FASEB J 2020 34 6 8641 8652 10.1096/fj.202000242R 32359123
Zhu Z, Peng X, Li X et al (2020) HMGB1 impairs endothelium-dependent relaxation in diabetes through TLR4/eNOS pathway. FASEB J 34(6):8641–8652. 10.1096/fj.202000242R32359123
57. Garcia AN Casanova NG Kempf CL eNAMPT Is a novel damage-associated molecular pattern protein that contributes to the severity of radiation-induced lung fibrosis Am J Respir Cell Mol Biol 2022 66 5 497 509 10.1165/rcmb.2021-0357OC 35167418
Garcia AN, Casanova NG, Kempf CL et al (2022) eNAMPT Is a novel damage-associated molecular pattern protein that contributes to the severity of radiation-induced lung fibrosis. Am J Respir Cell Mol Biol 66(5):497–509. 10.1165/rcmb.2021-0357OC35167418
